267 related articles for article (PubMed ID: 20040702)
1. Integrase inhibitors: a novel class of antiretroviral agents.
Schafer JJ; Squires KE
Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients.
D'Abbraccio M; Busto A; De Marco M; Figoni M; Maddaloni A; Abrescia N
AIDS Rev; 2015; 17(3):171-85. PubMed ID: 26450805
[TBL] [Abstract][Full Text] [Related]
4. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
Stock I
Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269
[TBL] [Abstract][Full Text] [Related]
5. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Kulkarni R; Hluhanich R; McColl DM; Miller MD; White KL
Antimicrob Agents Chemother; 2014 Oct; 58(10):6145-50. PubMed ID: 25092710
[TBL] [Abstract][Full Text] [Related]
6. Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
Wills T; Vega V
Expert Opin Investig Drugs; 2012 Mar; 21(3):395-401. PubMed ID: 22321026
[TBL] [Abstract][Full Text] [Related]
7. Next-generation integrase inhibitors : where to after raltegravir?
Karmon SL; Markowitz M
Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
9. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
[TBL] [Abstract][Full Text] [Related]
10. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
Lennox JL
Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
[TBL] [Abstract][Full Text] [Related]
11. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Correll T; Klibanov OM
Pharmacotherapy; 2008 Jan; 28(1):90-101. PubMed ID: 18154479
[TBL] [Abstract][Full Text] [Related]
12. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
13. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
14. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
15. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.
Elion R; Molina JM; Ramón Arribas López J; Cooper D; Maggiolo F; Wilkins E; Conway B; Liu YP; Margot N; Rhee M; Chuck SL; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):494-7. PubMed ID: 23807156
[TBL] [Abstract][Full Text] [Related]
18. Elvitegravir: a review of its use in adults with HIV-1 infection.
Deeks ED
Drugs; 2014 Apr; 74(6):687-97. PubMed ID: 24671908
[TBL] [Abstract][Full Text] [Related]
19. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
Lampiris HW
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):13-20. PubMed ID: 22149610
[TBL] [Abstract][Full Text] [Related]
20. Update on raltegravir and the development of new integrase strand transfer inhibitors.
Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
